Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

1 Top TSX Undervalued Stock to Buy Right Now

Published 2021-08-20, 07:00 p/m
Updated 2021-08-20, 07:15 p/m
1 Top TSX Undervalued Stock to Buy Right Now

1 Top TSX Undervalued Stock to Buy Right Now

As we (hopefully) head toward the other side of the pandemic, investors are largely looking for a top undervalued stock to put in their portfolios. As it happens, the TSX has a few great options to choose from right now.

However, picking the right one for a specific portfolio isn’t that easy.

In this article, I’m going to highlight why I think Manulife Financial (TSX:MFC)(NYSE:MFC) is a top undervalued stock to consider right now.

Excellent fundamentals driving this undervalued stock Manulife Financial is one of the top life insurance companies around the world, with a market capitalization of approximately $48 billion. The company provides health insurance, life insurance, annuity, pension, and more in North America and Asia.

What’s increasingly important for investors to focus on with Manulife is the company’s international operations. Indeed, approximately 35% of the company’s revenue comes from its Asia operations. And Manulife has recently made a bigger investment in its Asian insurance arm to grow in this high-growth market.

Accordingly, Manulife’s valuation of less than seven times earnings looks absurd in this context. The fact that Manulife stock pays out a dividend yield of 4.5% makes this an extremely undervalued stock to considered today. Indeed, Manulife ticks most of the boxes for conservative long-term investors today.

Better-than-expected Q2 earnings As an insurance company, Manulife has been hit hard by the pandemic. A reversion toward near-zero interest rates isn’t a great thing for insurers. This is because companies like Manulife earn money on the spread between what they earn on their invested premiums (before claims).

However, with interest rates expected to rise soon, Manulife’s outlook remains strong. Additionally, this past quarter, the company posted impressive results relative to the current environment.

The company’s wealth and asset management operations saw revenue growth of nearly 50% to $356 million in the three-month period ending on June 30. Manulife’s earnings received a boost due to 7.6% growth in its Asian operations. This increase has helped the life insurer to make up for its drop in core earnings in the U.S. and Canada. Nevertheless, Manulife’s earnings fell by 21% and 7% in the U.S. and Canada, respectively. This drop was expected.

Bottom line Manulife’s stock price has surged nearly 15% in the current year. However, I think there’s a lot more room for this undervalued stock to run.

Indeed, given the company’s current valuation and positioning coming out of this pandemic, I think Manulife could be a real long-term winner for investors at these levels. The company’s strong market share in Asia and a recovery in its North American business is positive. Indeed, Manulife is a top pick on many fronts. This is a growth, value, and income play. Such a stock is simply very hard to find today.

The post 1 Top TSX Undervalued Stock to Buy Right Now appeared first on The Motley Fool Canada.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.